Pfizer, Starboard

What activist hedge fund Starboard wants from Pfizer
Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO Jeff Smith.
Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance, particularly for its record for producing profitable new drugs.
Pfizer has “significantly overpaid” for recent acquisitions: Starboard Value
Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance on the pharma giant. Read more here.
Starboard urges Pfizer board to ‘hold management accountable’, FT reports
Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable
Pfizer taps Vanguard veteran for board amid fight with Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund Starboard Value.
Starboard calls for Pfizer board to ‘hold management accountable’
Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference
FiercePharma3d
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.
pharmaphorum3d
Starboard spells out its concerns with Pfizer's direction
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
BioPharma Dive3d
Starboard makes case for change at Pfizer, citing research, M&A missteps
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
Starboard Value CEO Jeff Smith: Pfizer needs to do a better job disciplining itself on investments
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
BioSpace3d
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Investor's Business Daily on MSN3d
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best ...